tradingkey.logo
tradingkey.logo

BioXcel jumps after mid-stage trial shows drug eases opioid withdrawal symptoms

ReutersMar 5, 2026 12:39 PM

Shares of drugmaker BioXcel Therapeutics BTAI.O rise 23% to $2.03 premarket

Co says its experimental drug, BXCL501, helped ease symptoms of opioid withdrawal by over 30% in a mid-stage study with 80 adults

Adds that BXCL501 outperformed lofexidine, a non-opioid taken four times a day for withdrawal symptoms

Also notes fewer side effects for BXCL501 vs. lofexidine, including lower rates of low blood pressure and no reported sedation

BTAI fell ~73% in 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI